MedTrace Logo

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

NCT02967679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-11-02

Study results available
· View outcomes & findings →

Summary

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Conditions

Interventions

DRUG

MD1003

Sponsors & Collaborators

  • MedDay Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Alain CREANGE, MD · Hôpital Henri Mondor, Créteil, France

  • Frederic Sedel, MD · Medday Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-05
Primary Completion
2019-03-18
Completion
2019-03-18

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967679 on ClinicalTrials.gov